NCT00481169View on ClinicalTrials.gov

Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women

PHASE3CompletedINTERVENTIONAL
Enrollment

1,742

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

July 31, 2004

Study Completion Date

September 30, 2004

Conditions
Osteoporosis
Interventions
DRUG

Bazedoxifene Acetate (TSE-424)

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00481169 - Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women | Biotech Hunter | Biotech Hunter